Asia Pac Allergy.
2019 Jan;9(1):e7. 10.5415/apallergy.2019.9.e7.
Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
- Affiliations
-
- 1National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan. nishima.sankei.ac@mail.hosp.go.jp
- 2Medical Division, Novartis Pharma K.K., Tokyo, Japan.
- 3University of Manchester, Manchester, UK.
- KMID: 2433668
- DOI: http://doi.org/10.5415/apallergy.2019.9.e7
Abstract
- Childhood asthma is one condition within a family of allergic diseases, which includes allergic rhinitis, atopic dermatitis, and food allergy, among others. Omalizumab is an anti-IgE antibody therapy that was approved in Japan for children with asthma and added to the Japanese pediatric asthma guidelines in 2017. This review highlights the Japanese clinical perspectives in pediatric allergic asthma, and consideration for allergic comorbidities, and reflects on omalizumab clinical trials in progress to present comprehensive future opportunities.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Is Omalizumab a Problem-Solving Remedy in Severe Asthma?
- Real-life Efficacy of Omalizumab After 9 Years of Follow-up
- Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea
- Prevalence and comorbidity of allergic diseases in preschool children
- Omalizumab in recurring larynx angioedema: a case report
